2015
DOI: 10.1093/neuonc/nou365
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: PX-866 was relatively well tolerated. Overall response rate was low, and the study did not meet its primary endpoint; however, 21% of participants obtained durable stable disease. This study also failed to identify a statistically significant association between clinical outcome and relevant biomarkers in patients with available tissue.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
56
0

Year Published

2016
2016
2023
2023

Publication Types

Select...
7
3

Relationship

0
10

Authors

Journals

citations
Cited by 72 publications
(56 citation statements)
references
References 27 publications
0
56
0
Order By: Relevance
“…A recent phase II study evaluating everolimus, temozolomide, and RT in patients with newly diagnosed glioblastoma showed no appreciable survival benefit of the combination compared to historical controls treated with conventional therapy (65). The newer selective PI3K inhibitor PX-866 had a low overall response rate, with median PFS at 6 months of only 17% in a phase II study of patients with recurrent GBM (66). However, 21% of participants had durable stable disease even if no association between stable disease and molecular biomarkers was seen.…”
Section: Inhibitors Of Growth Factors and Their Receptors Inhibitorsmentioning
confidence: 99%
“…A recent phase II study evaluating everolimus, temozolomide, and RT in patients with newly diagnosed glioblastoma showed no appreciable survival benefit of the combination compared to historical controls treated with conventional therapy (65). The newer selective PI3K inhibitor PX-866 had a low overall response rate, with median PFS at 6 months of only 17% in a phase II study of patients with recurrent GBM (66). However, 21% of participants had durable stable disease even if no association between stable disease and molecular biomarkers was seen.…”
Section: Inhibitors Of Growth Factors and Their Receptors Inhibitorsmentioning
confidence: 99%
“…PX-866 could bind with the catalytic domain of ATP and it acts as an irreversible inhibitor. Though PX-866 could increase median survival time of the animals and show significant anti-tumor activity in GBM xenograft models [54, 55], the recent completed clinical study showed the overall response rate was low (NCT01259869) [56]. …”
Section: The Development Of Targeted Therapy Towards Egfr and Pi3k/akmentioning
confidence: 99%
“…Targeted agents aiming to inhibit oncogenic pathways such as enzastaurin, everolimus, PX-866, selinexor or dasatinib showed disappointing results [53,[108][109][110][111]. The phase II trial evaluating the multikinase inhibitor dasatinib only included patients with activation or overexpression of ≥2 putative dasatinib targets (ie, SRC, c-KIT, EPHA2, and PDGFR), nevertheless with poor efficacy results [111].…”
Section: Targeted Therapymentioning
confidence: 99%